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Abstract
Background There is a proven relationship between
obesity and several cancers including breast, endometrium,
colorectal, and esophagus. With the increasing incidence of
both obesity and thyroid cancer, we designed the present
study to investigate a causal relationship between leptin,
which is one of the well known adipokines, and well-dif-
ferentiated thyroid cancer (WDTC).
Methods Serum leptin levels were measured in 30
patients with WDTC and compared to 30 healthy control
subjects before and 1 month after surgery. Other parame-
ters studied included age, sex, body mass index, meno-
pausal status in women, lymph node status, tumor size, and
disease multifocality.
Results There were no differences between the two groups
regarding age and sex. Preoperative leptin levels were
higher in the WDTC patients when compared to the control
patients [19.25 (1.50–109.60) vs 0.90 (0.50–11.80) ng/ml,
p\0.001, group 1 vs group 2, respectively]. A signiﬁcant
drop in leptin levels 1 month after surgery occurred in the
WDTC group, falling from 19.25 (1.50–109.60) to 0.90
(0.60–8.90) ng/ml (p\0.001). This did not occur in the
control group (p = 0.274). Lymph node involvement,
tumor size, and multifocality had no effect on leptin levels,
although trends were observed (p = 0.48, 0.079, and
0.064), respectively.
Conclusions Serum leptin levels were signiﬁcantly higher
in WDTC patients when compared to control group
patients, with a signiﬁcant drop after surgery. Leptin may
play a role in diagnosis of WDTC; however, its prognostic
value is still undetermined.
Introduction
Obesity is a worldwide major health issue with an
increasing prevalence [1]. In addition to being a medical
condition increasing the risk of heart disease and diabetes,
obesity is associated with several cancers through a family
of metabolically active adipocytokines including tumor
necrosis factor (TNF)-alpha, interleukin (IL)-6, type 1
plasminogen activator inhibitor, adiponectin, and leptin [2–
5]. The exact mechanisms explaining this association are
still at large; however, several theories have been proposed,
including hyperinsulinemia and a state of chronic low level
inﬂammation associated with obesity, with abnormal
cytokine production affecting tumor initiation and pro-
gression [6, 7]. Leptin, one of the most abundant and most
investigated adipokines, was thought to have a role in
regulating body weight solely by regulating body fat stores,
but leptin has functions that extend beyond food intake and
energy balance regulation, being also a metabolic and
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metabolism, normal sexual maturation, and reproduction,
and it also has effects on the hypothalamic–pituitary–
adrenal, thyroid and growth hormone axes, hematopoiesis,
and the immune system [8, 9]. With respect to its diverse
functions in immunity, leptin may have a major role in
oxidation, which is an important risk factor in carcino-
genesis. Indeed, obesity has long been recognized to be a
risk factor for tumorigenesis, and accumulating evidence
suggests that leptin is a potential link between obesity and
cancer development. Further studies have shown it to act as
a mitogenic agent promoting the proliferation and inva-
siveness of certain cancer cells [10].
Papillary thyroid carcinoma (PTC) is the most common
neoplasm of the thyroid, accounting for 80–85 % of all
thyroid cancers [11]. Increasing incidence of differentiated
thyroid cancers has been observed in both men and women
across all tumor sizes [12]. PTC is found in a variety of
morphologic variants, like the follicular variant of papillary
thyroid carcinoma (FVPTC). It is usually clinically indo-
lent, although rarely it may present with local invasion or
distant metastases, which may adversely affect survival
[13]. The relation between obesity and thyroid cancer has
recently been studied, showing a higher prevalence of
thyroid cancer in the obese population [14]. The present
study was designed to investigate the relation between
serum levels of leptin and well-differentiated thyroid car-
cinoma (WDTC) and to evaluate its correlation with patient
and tumor characteristics.
Methods
Sixty patients were enrolled in this study and were divided
into two groups. Group 1 (n = 30) comprised patients with
WDTC diagnosed by ﬁne needle aspiration cytology
(FNAC),andgroup2(n = 30)whowerethecontrolpatients
with benign thyroid nodules. All patients included in this
study were admitted to Alexandria Main University hospital
betweenSeptember2011andSeptember2012.Aninformed
consent form was signed by all patients according to a pro-
tocol approved by the Ethics Committee of the hospital.
All patients were subjected to complete physical
examination, standard biochemical tests, and thyroid
function tests. Both FNAC and ultrasound scans were
performed in all patients, with a CT requested when nec-
essary to evaluate extrathyroidal tumor invasion.
Exclusion criteria included diabetes mellitus, hyperten-
sion, thyroid hormonal proﬁle abnormalities, either
hyperthyroidism or hypothyroidism, and ongoing hormonal
therapy, such as oral contraceptive pills, estrogen prepa-
rations, and thyroid hormone preparations. Patients with
evidence of recent systemic illness or receiving
medications for other medical conditions were also exclu-
ded from the study (Fig. 1).
All patients underwent either total thyroidectomy (TT)
or hemithyroidectomy. Central neck dissection (CND) was
done for those with positive central lymph nodes, and
functional neck dissection (FND) was performed in
patients with lateral nodal neck disease. Histopathological
examination of the resected specimens was performed.
Pathological criteria including tumor size, tumor patho-
logical type, extrathyroidal invasion, multifocality, lym-
phovascular invasion, lymph node status, and presence of
lymphocytic thyroiditis were reported.
Patient demographics and anthropometric measurements
including weight, height, and body mass index (BMI) were
recorded. Samples were collected with the patient in the
fasting state in the morning. Sample collection, processing,
and storage were done according to the instructions of the
reference laboratory and the kits. Samples for leptin level
measurements were taken from the patients preoperatively
and again 1 month postoperatively.
Assays
Serum samples were kept at -40 C until analysis. All
samples from each patient were run in the same assay.
Serum leptin was measured by the DIAsource Leptin-
EASIA Kit, (DIAsource ImmunoAssays, Louvain-la-Neuve,
Belgium).
Statistical analysis
Data were collected, tabulated, and then analyzed using
IBM SPSS software package version 20.0., and statistically
analyzed with the Shapiro–Wilk test, the D’Agastino test,
and the Mann–Whitney test. Signiﬁcance of the obtained
results was judged at the 5 % level.
Results
In group 1, 15 (50 %) patients underwent TT with FND, 5
(16.7 %)patientsunderwentTTwithCND,8(26.7 %)patients
underwent TT, and 2 (6.6 %) patients who had a diagnosis of
micropapillary carcinoma underwent hemithyroidectomy with
no further surgery. In group 2 (controls) 22 (73.3 %) patients
underwent TT and 8 (26.7 %) patients underwent hemithy-
roidectomy. All patients had their leptin levels measured pre-
operatively and 1 month after the operation.
Demographics and patient characteristics
There was no signiﬁcant difference between the two groups
regarding age and gender. The BMI for all patients was
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123recorded and compared in both study groups with no sig-
niﬁcant statistical difference The menstrual status of
female patients in both groups was compared with no
signiﬁcance between studied groups (p = 0.462) (Table 1).
Comparison between serum leptin levels in both study
groups
Both preoperative and postoperative serum leptin levels
were measured in the two study groups. The preoperative
serum leptin levels were signiﬁcantly higher in the WDTC
patients than in the controls (19.25 [1.50–109.60] vs 0.90
[0.50–11.80] ng/ml; p\0.001, group 1 vs group 2,
respectively) (Table 2).
There was a signiﬁcant drop in serum leptin levels
1 month after surgery in the WDTC group, falling from
19.25 (1.50–109.60) to 0.90 (0.60–8.90) ng/ml (p\0.001).
In contrast, for the control group there was no signiﬁcant
difference between preoperative and postoperative serum
leptin levels (p = 0.274).
One month after surgery, there was no signiﬁcant dif-
ference between serum leptin levels in both groups: 0.90
(0.60–8.90) vs 0.80 (0.50–10.80) ng/ml, group 1 vs group
2 respectively (p = 0.532).
Comparison between leptin levels in different BMI
subgroups
A subanalysis of the two groups was performed based on
the patients’ BMI. They were subdivided into underweight
(BMI\18), normal (BMI 18 to\25), overweight (BMI 25
to \30), and obese (BMI C30) (Table 3). Leptin levels
were measured and compared in the four subgroups before
and after surgery. There was no signiﬁcant difference
Fig. 1 Flow chart showing the
patients with thyroid disease
excluded from the study
Table 1 Relationship between demographic data and leptin
expression
Group 1 Group 2 p value
Gender
Male 12 (40.0 %) 6 (20.0 %) 0.091
Female 18 (60.0 %) 24 (80.0 %)
Age, years 55.50 (18.0–67.0) 35.50 (22.0–67.0) 0.157
BMI 24.87 ± 5.84 25.03 ± 4.51 0.902
Menstrual status n = 18 n = 24
Pre-menopause 13 (72.2 %) 20 (83.3 %) 0.462
Post-menopause 5 (27.8 %) 4 (16.7 %)
Table 2 Comparison between cases and controls regarding leptin
level
Group 1 Group 2 p value
Preoperative
leptin level,
ng/ml
19.25 (1.50–109.60) 0.90 (0.50–11.80) \0.001*
Postoperative
leptin level,
ng/ml
0.90 (0.60–8.90) 0.80 (0.50–10.80) 0.532
p value \0.001* 0.274
* Statistically signiﬁcant
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123between the two groups regarding BMI. There was, how-
ever, a signiﬁcant postoperative decrease in serum leptin
levels in all BMI subgroups in WDTC patients when
compared to their preoperative serum leptin levels
(Table 4).
Comparison between leptin levels according
to menopausal status
Of 30 patients in the WDTC group, 18 (60 %) were
females, and in the control group there were 24 (80 %)
females. Female patients in both groups were classiﬁed
according to their menstrual status into premenopausal or
postmenopausal (Table 5). There was no statistically sig-
niﬁcant difference between preoperative serum leptin lev-
els in premenopausal and postmenopausal WDTC female
patients: 11.50 (1.50–44.80) and 34.90 (10.0–34.90) ng/ml,
respectively (p = 0.213).
There was a signiﬁcant decrease in serum leptin levels
one month postoperatively for both premenopausal and
postmenopausal WDTC patients (p = 0.001 and 0.038),
respectively; however, the postmenopausal group of
patients still had signiﬁcantly higher serum leptin levels
8.90 (6.90–8.90) ng/ml in comparison to the premenopau-
sal group 2.10 (0.60–6.80) ng/ml (p = 0.001).
In the control group there was no signiﬁcant difference
in serum leptin levels between pre- and postmenopausal
female patients either preoperatively or postoperatively
(p = 0.640 and 0.784), respectively, and there was no
signiﬁcant drop in serum leptin levels after surgery in both
pre- and postmenopausal patients groups (p = 0.115 and
1.0).
Relationship between clinicopathological criteria
and leptin expression
The postoperative histological examination of speci-
mens from patients with a diagnosis of WDTC showed
that 25 (83 %) patients had PTC, 2 (7 %) patients had
FVPTC, and 3 (10 %) patients had follicular carcinoma.
The comparison of leptin levels of these three groups
showed no signiﬁcant difference (p = 0.106), as shown
in Fig. 2.
Lymph node metastases were detected in 20 (66.6 %)
patients in the WDTC group. There was a trend for pre-
operative serum leptin levels to be higher in patients with
cervical lymph node metastasis—34.25 (1.50–109.60) ng/
ml—compared to those without lymph node metastasis—
19.25 (4.20–44.80) ng/ml, however did not reach statistical
signiﬁcance (p = 0.480). There was also a trend for serum
leptin levels to be higher in multifocal primary thyroid
tumors (p = 0.064; Fig. 2). A positive trend was also
apparent between the size of the tumor and preoperative
leptin level; however, it did not reach a signiﬁcant value
(p = 0.079; Fig. 3).
Table 3 Comparison between both groups regarding BMI
Group 1 Group 2 p value
BMI
Underweight (\18) 5 (16.7) 1 (3.3) 0.195
Normal (18 to\25) 11 (36.7) 13 (43.3) 0.598
Overweight (25 to\30) 7 (23.3) 11 (36.7) 0.260
Obese (C30) 7 (23.3) 5 (16.7) 0.519
p value 0.256
Table 4 Comparison between
preoperative and postoperative
leptin levels in WDTC with
respect to BMI subgroups
* Statistically signiﬁcant
Underweight
(\18) (n = 5)
Normal (18 to
\25) (n = 11)
Overweight (25 to
\30) (n = 7)
Obese (C30)
(n = 7)
Preoperative leptin
level, ng/ml
24.0 (11.50–24.0) 4.20 (1.50–109.60) 22.80 (15.70–57.0) 34.90 (10.0–44.80)
Postoperative leptin
level, ng/ml
0.70 (0.70–3.70) 0.80 (0.60–2.10) 0.80 (0.60–4.50) 6.90 (6.80–8.90)
p value 0.038* 0.003* 0.017* 0.017*
Table 5 Comparison between preoperative and postoperative leptin
levels in different groups according to menstrual status
Pre-menopause Post-menopause p value
Group 1
n 13 5
Preoperative
leptin
11.50 (1.50–44.80) 34.90 (10.0–34.90) 0.213
Postoperative
leptin
2.10 (0.60–6.80) 8.90 (6.90–8.90) 0.001*
p value 0.001* 0.038*
Group 2
n 20 4
Preoperative
leptin
2.55 (0.50–11.80) 3.55 (0.60–7.70) 0.640
Postoperative
leptin
0.80 (0.50–10.80) 3.20 (0.70–6.50) 0.784
p value 0.115 1.000
* Statistically signiﬁcant
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Several studies have shown that leptin can act as a growth
factor promoting proliferation of transformed cells and
stimulating angiogenesis in cancers like endometrium and
breast [15, 16]. There is a proven relationship between
thyroid gland function and leptin, as both leptin and thyroid
hormones regulate the metabolic machinery, as well as
energy storage and expenditure. It has been shown that
leptin serum levels ﬂuctuate in response to alterations in
thyroid activity [17]. This correlation between leptin and
thyroid hormone status has been extensively studied, with
discrepancies in published results [18–21]. An explanation
for these controversial results may arise from the difﬁculty
in matching patients to controls regarding the metabolic
status, as the BMI, which is the most commonly used
confounding factor is not an accurate reﬂection of body
composition.
Owing to the relation between leptin and both cancer
development and the thyroid gland, we hypothesized
whether leptin levels would correlate with a diagnosis of
thyroid cancer and whether or not higher levels would
predict a more aggressive tumor behavior with a greater
potential to invade and metastasize. This would reﬂect on
the strictness and duration of patient follow-up and would
highlight possibilities of future disease recurrence. This is
especially important in Egypt with limited follow-up
facilities due to the rural nature, resulting in patients being
lost to follow-up and re-presenting several years later with
very aggressive disease, as previously reported by our
group [22]. In the present study we compared changes in
serum leptin levels in patients with WDTC before and after
surgery and in control subjects.
Two factors in our study support the relationship
between leptin and thyroid cancer. First, we found that the
serum leptin levels in WDTC patients were higher than
those in their control group counterparts (p\0.001).
Second, there was a signiﬁcant drop in leptin levels
1 month after thyroidectomy compared to pre-thyroidec-
tomy levels. It has been reported that in states of thyroid
hormone deﬁciency, leptin levels increase in parallel with
overexpression of thyrotropin releasing hormone and thy-
roid stimulating hormone (TSH) [17]. It would have
therefore been acceptable if leptin levels had increased
post-thyroidectomy as a result of the occurrence of inten-
tional hypothyroidism, as we do not replace our thyroid
cancer patients with thyroid hormones prior to radioactive
iodine ablation. The serum leptin levels did not rise, and
the signiﬁcant decrease in the leptin levels in WDTC
patients were paradoxical, and therefore support the con-
cept of a relationship between leptin and thyroid cancer,
making leptin a possible etiologic factor in thyroid carci-
nogenesis. In the benign disease group, there was no sig-
niﬁcant change in serum leptin levels, possibly due to the
fact that these patients were immediately replaced with
thyroxine and were euthyroid at the time of leptin
measurement.
Following documentation of the primary hypothesis, we
sought to investigate other factors that might have inﬂu-
enced leptin serum levels in either group. Because leptin is
synthesized and secreted mainly by adipose tissue, and
because its plasma levels strongly correlate with BMI [23],
we calculated the patients’ BMI in both groups before and
after surgery; we could not, however, detect any signiﬁcant
Fig. 2 A correlation between histolopathological characteristics and
leptin levels. There was no correlation between serum leptin levels
and tumor type (p = 0.106), cervical lymph node metastases
(p = 0.48) or number of foci within the thyroid gland (p = 0.064),
although trends were observed
Fig. 3 A correlation between primary tumour size and leptin levels.
No correlation was observed between the primary cancer size within
the thyroid gland and leptin levels (p = 0.079)
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123differences. Moreover, leptin levels decreased postopera-
tively in all subgroups of WDTC patients irrespective of
BMI.
Because leptin may also be affected by menopausal
status due to associated hormonal changes, both groups
were analyzed based on their menopausal status. Although
no differences could be detected in either group preoper-
atively, both premenopausal and postmenopausal women
in the WDTC group had a signiﬁcant reduction in leptin
levels following surgery. The postoperative leptin levels in
WDTC postmenopausal women, however, remained sig-
niﬁcantly higher when compared to premenopausal
women. This ﬁnding contradicts previous studies that
reported a decline in serum leptin levels with advancing
age and in postmenopausal women [24, 25]. The lack of
difference in leptin levels between premenopausal and
postmenopausal women in the WDTC group might have
been masked by the presence of the cancer as documented
earlier. This would have been expected to drop following
surgery, especially in the postmenopausal subgroup. The
signiﬁcantly higher leptin levels in postmenopausal women
following thyroid surgery could be explained by the
hypothyroid status itself, as this did not occur in the benign
disease group patients, who were euthyroid. Teixeira et al.
[26] reported that in postmenopausal women, there is a
stronger inﬂuence of thyroid status on leptin levels through
a stronger correlation between TSH and leptin leading to
higher leptin levels in this population. They showed that
this correlation did not occur in premenopausal women;
moreover, leptin levels were reduced with thyroxine
replacement.
We then investigated the presence of a correlation
between histopathological ﬁndings and serum leptin levels.
In WDTC, the size of the primary tumor, multifocality, and
lymph node status are essential criteria in risk stratiﬁcation
into either low risk or high risk and will predict disease
recurrence [27, 28]. Although trends were demonstrated
between leptin levels and each of tumor size (p = 0.079),
malignant lymph node involvement (p = 0.48), and mul-
tifocal disease (p = 0.064), the differences did not reach
statistical signiﬁcance. Cheng et al. [29, 30] observed a
strong association between leptin tissue expression and
both tumor size and metastatic lymph nodes in their clin-
icopathological study, with further work showing the role
of leptin in tumor cell migration in PTC.
To conclude, higher leptin levels were associated with a
diagnosis of WDTC with a signiﬁcant drop in the leptin
levels following surgery. Other prognostic factors, like
lymph node status, age, tumor size, and multifocal disease,
had no effect on leptin levels. Future studies should focus
on ﬁnding a correlation between cancer activation path-
ways, leptin receptor tissue expression, and serum leptin
levels, which could then be used as a tumor marker in the
clinical setting.
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